Nebivolol

CHEMBL434394 Phase 4 Aprobado Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
405.4 g/mol
LogP
3.0
Phase
4

This highly selective beta-blocker is used to treat high blood pressure and heart failure by slowing the heart rate and reducing the force of heart contractions. It also has unique blood vessel-relaxing properties that help lower blood pressure further.

Peso molecular

405,4000 g/mol

LogP

3,00

TPSA

71,00 Ų

Regla de cinco de Lipinski

Cumple

Áreas terapéuticas

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Estructura 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

OC(CNCC(O)C1CCc2cc(F)ccc2O1)C1CCc2cc(F)ccc2O1

InChI

InChI=1S/C22H25F2NO4/c23-15-3-7-19-13(9-15)1-5-21(28-19)17(26)11-25-12-18(27)22-6-2-14-10-16(24)4-8-20(14)29-22/h3-4,7-10,17-18,21-22,25-27H,1-2,5-6,11-12H2

Molecular Formula

C22H25F2NO4

HBD / HBA

3 / 7

Enlaces Rotables

6

Átomos Pesados

29

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Preguntas frecuentes

This highly selective beta-blocker is used to treat high blood pressure and heart failure by slowing the heart rate and reducing the force of heart contractions. It also has unique blood vessel-relaxing properties that help lower blood pressure further.

Yes, Nebivolol is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL434394. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 71301. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

Aviso médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.